{
  "asset": "IMBRUVICA (ibrutinib)",
  "query_terms": [
    "IMBRUVICA (ibrutinib)",
    "ibrutinib",
    "IMBRUVICA"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT04016636",
      "title": "\"Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia (CLL): Argentinian Experience\"",
      "overall_status": "COMPLETED",
      "phase": null,
      "conditions": [
        "CLL"
      ],
      "lead_sponsor": "Mela Osorio Maria Jose",
      "collaborators": [
        "Janssen-Cilag Ltd."
      ],
      "interventions": [
        "Standard of Care"
      ],
      "last_update": "2023-02-16",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04016636"
    },
    {
      "nct_id": "NCT02556892",
      "title": "Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "phase": "Phase 1",
      "conditions": [
        "Lymphocytic Leukemia"
      ],
      "lead_sponsor": "Janssen Pharmaceutical K.K.",
      "collaborators": [],
      "interventions": [
        "Ibrutinib"
      ],
      "last_update": "2019-08-14",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02556892"
    },
    {
      "nct_id": "NCT02959944",
      "title": "A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)",
      "overall_status": "COMPLETED",
      "phase": "Phase 3",
      "conditions": [
        "Chronic Graft Versus Host Disease"
      ],
      "lead_sponsor": "Pharmacyclics LLC.",
      "collaborators": [
        "Janssen Research & Development, LLC"
      ],
      "interventions": [
        "ibrutinib",
        "Placebo",
        "Prednisone"
      ],
      "last_update": "2023-03-30",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02959944"
    },
    {
      "nct_id": "NCT02758665",
      "title": "A Prospective, Open-label, Multicentre Phase-II Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Physically Fit or Unfit Patients With Previously Untreated Chronic Lymphocytic Leukemia (Cll) With tp53 Deletion (17p-) and/or Mutation",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Leukemia, Lymphocytic, Chronic"
      ],
      "lead_sponsor": "University of Ulm",
      "collaborators": [
        "German CLL Study Group",
        "Roche Pharma AG",
        "Janssen-Cilag Ltd.",
        "AbbVie"
      ],
      "interventions": [
        "ibrutinib",
        "obinutuzumab",
        "venetoclax"
      ],
      "last_update": "2023-01-17",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02758665"
    },
    {
      "nct_id": "NCT02532257",
      "title": "An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Ann Arbor Stage II Follicular Lymphoma",
        "Ann Arbor Stage II Marginal Zone Lymphoma",
        "Ann Arbor Stage III Follicular Lymphoma",
        "Ann Arbor Stage III Marginal Zone Lymphoma",
        "Ann Arbor Stage IV Follicular Lymphoma",
        "Ann Arbor Stage IV Marginal Zone Lymphoma",
        "CD20 Positive",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3a Follicular Lymphoma"
      ],
      "lead_sponsor": "M.D. Anderson Cancer Center",
      "collaborators": [
        "National Cancer Institute (NCI)",
        "Janssen, LP"
      ],
      "interventions": [
        "Ibrutinib",
        "Laboratory Biomarker Analysis",
        "Lenalidomide",
        "Rituximab"
      ],
      "last_update": "2024-09-24",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02532257"
    },
    {
      "nct_id": "NCT02717611",
      "title": "A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "lead_sponsor": "Acerta Pharma BV",
      "collaborators": [],
      "interventions": [
        "ACP-196 (acalabrutinib)"
      ],
      "last_update": "2026-01-08",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02717611"
    },
    {
      "nct_id": "NCT01886872",
      "title": "A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Stage I Chronic Lymphocytic Leukemia",
        "Stage II Chronic Lymphocytic Leukemia",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage IV Chronic Lymphocytic Leukemia"
      ],
      "lead_sponsor": "National Cancer Institute (NCI)",
      "collaborators": [],
      "interventions": [
        "Bendamustine Hydrochloride",
        "Biospecimen Collection",
        "Bone Marrow Aspiration",
        "Bone Marrow Biopsy",
        "Computed Tomography",
        "Ibrutinib",
        "Laboratory Biomarker Analysis",
        "Quality-of-Life Assessment",
        "Rituximab"
      ],
      "last_update": "2025-11-28",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT01886872"
    },
    {
      "nct_id": "NCT04908228",
      "title": "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "lead_sponsor": "Paolo Ghia",
      "collaborators": [],
      "interventions": [
        "Ibrutinib and obinutuzumab"
      ],
      "last_update": "2023-10-03",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04908228"
    },
    {
      "nct_id": "NCT02268851",
      "title": "A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies",
      "overall_status": "COMPLETED",
      "phase": "Phase 1",
      "conditions": [
        "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "lead_sponsor": "Dana-Farber Cancer Institute",
      "collaborators": [
        "TG Therapeutics, Inc.",
        "The Leukemia and Lymphoma Society",
        "Blood Cancer Research Partnership"
      ],
      "interventions": [
        "TGR-1202",
        "Ibrutinib"
      ],
      "last_update": "2024-11-15",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02268851"
    },
    {
      "nct_id": "NCT02455297",
      "title": "A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib",
      "overall_status": "TERMINATED",
      "phase": "Phase 2",
      "conditions": [
        "Lymphoma, Mantle-Cell"
      ],
      "lead_sponsor": "Bayer",
      "collaborators": [],
      "interventions": [
        "Copanlisib (BAY80-6946)"
      ],
      "last_update": "2017-10-02",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02455297"
    }
  ]
}